MAGEA3 and non-small cell lung carcinoma: Compared to placebo, adjuvant treatment with MAGE-A3 immunotherapeutic did not improve DFS in patients with MAGE-A3-positive surgically resected NSCLC (hazard ratio (HR) 1.02, 95% confidence interval (CI) 0.89–1.18; p = 0.74).